Abstract: A novel composition is disclosed which is useful as a sterilization indicator that can distinguish clearly between the types of sterilization employed, e.g., that indicates whether sterilization was accomplished by steam or dry heat. The novel composition comprises (1) thiobarbituric acid and (2) at least one suitable reacting moiety being capable of reacting with said acid under temperature and humidity conditions of steam and dry heat sterilization to form a colored product. Suitable reacting moieties disclosed are (a) parabanic acid and (b) dimethyl oxalate and urea.

Abstract: New and pharmacologically useful pharmaceutically acceptable acid addition salts are disclosed for the 16.beta.-mono-quaternary ammonium derivatives of either the 2.beta., 16.beta.-bis-piperdino-3-.alpha., 17.beta.-dihydroxy-5.alpha.-androstane 3.alpha., 17.beta.-di-lower aliphatic esters of the 2.beta., 16.beta.-bis-piperidino-3.alpha.-hydroxy-5.alpha.-androstane-3.alpha.-lowe r aliphatic esters, which salts are surprisingly relatively stable in aqueous solutions, so that they provide stable aqueous injection preparations.

Abstract: Novel and stable compositions of matter are disclosed which change color sharply upon a transition from a liquid state to a solid state or from a solid state to a liquid state, which change of state is at substantially a predetermined temperature corresponding to a temperature to be measured.The constituents of the novel compositions of matter comprise:1. a solvent (I) consisting of a single substance or a mixture of substances and adapted to change from a solid state at substantially a predetermined temperature to a liquid state and2. an indicator system (II) consisting of one or more substances different from (I), characterized in that(a) (II) is soluble in (I) when the latter is in the liquid phase, and(b) (II) changes color visible to the naked eye when (I) passes from the solid to the liquid phase or from the liquid to the solid phase.Thermometers containing said stable compositions of matter are also disclosed.

Abstract: The invention relates to novel compounds of general formula I: ##STR1## and salts, esters and amides thereof, in which R.sub.1 and R.sub.2 represent hydrogen, alkyl or alkenyl (1-4 C),R.sub.3 represents hydrogen, halogen, hydroxy, alkyl (1-4 C) or alkoxy (1-4 C),n has the value 0, 1 or 2 andALK is a saturated or unsaturated hydrocarbon radical with 3-12 carbon atoms, in which a straight carbon chain in between the benzene rings is present, containing 3-8 carbon atoms, andthe dotted line indicates an optional extra bond between the first and second carbon counted from the phenyl ring, in case of an extra bond the group R.sub.2 and one hydrogen attached to said second carbon being absent, having valuable hypocholesterolaemic and hypotriglyceriolaemic properties.

Abstract: New and useful stable peroxidase compositions are disclosed which are particularly useful as reagents in enzyme immunoassay (EIA) tests. The novel peroxidase compositions contain polyvalent ions of groups 3 and 4 of the Periodic Table. These novel compositions are stable even at low concentrations of peroxidase, and are relatively invulnerable to freeze-drying. Preferably, the polyvalent ions selected are those of Al, Zn, Mg, Fe, and Cu.

Abstract: Novel and biologically active tetracyclic compounds are disclosed of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof, wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each hydrogen, hydroxy, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, halogen, or trifluoromethyl; R.sub.5 is hydrogen or C.sub.1 -C.sub.6 alkyl; and X is oxygen or methylene. Pharmaceutical compositions containing these compounds are disclosed to take advantage of CNS-inhibiting properties thereof, especially sedative and tranquillizing properties.

Abstract: New and useful steroids of the pregnane series and compositions therefor are disclosed of the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of H, F, OH, and OR.sub.2, and R.sub.2 is carbacyl of one to eighteen carbon atoms, which steroids exhibit useful pharmacological utility, to wit, progestational and/or ovulation-inhibiting activity.

Abstract: There are disclosed substrates of the formula: ##STR1## wherein: (a) R.sub.1 is H or C.sub.1 -C.sub.4 alkyl;(b) R.sub.2 is H or C.sub.1 -C.sub.4 alkyl with the proviso that R.sub.1 is H when R.sub.2 is alkyl, and with the proviso that R.sub.2 is H when R.sub.1 is alkyl;(c) R.sub.3 is a leaving group including hydroxy, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkoxalkoxy, C.sub.1 -C.sub.7 acyloxy, and trialkylsilyloxy of less than fifteen carbons; and(d) R.sub.5(1) and R.sub.5(2) are each H, C.sub.1 -C.sub.8 alkyl, or an optionally esterified or etherified hydroxy group including hydroxy, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkoxyalkoxy, C.sub.1 -C.sub.15 trialkylsilyloxy, C.sub.4 -C.sub.8 cycloalkoxy, C.sub.1 -C.sub.7 carboxyacyloxy, or unsubstituted heterocyclic ether of five to seven members, with the proviso that at least one of R.sub.5(1) and R.sub.5(2) is hydrogen.

Abstract: Cyclisation substrates are disclosed of the formula: ##STR1## wherein: (a) R.sub.1 is H or alkyl of one to four carbon atoms;(b) R.sub.2 is H or alkyl of one to four carbon atoms, with the proviso that R.sub.1 is H when R.sub.2 is alkyl, and with the proviso that R.sub.2 is H when R.sub.1 is alkyl;(c) R.sub.3 is a suitable leaving group selected from the group consisting of hydroxy, alkoxy of one to four carbons, alkoxyalkoxy of two to four carbons, acyloxy of one to about seven carbon atoms, and trialkylsilyloxy of less than fifteen carbons;(d) R.sub.4 is methyl; and(e) R.sub.5(1) and R.sub.

Abstract: The invention relates to an oral pharmaceutical preparation with androgenic activity on the basis of one or more esters of testosterone and/or 5.alpha.-dihydrotestosterone, the ester group of which has been derived exclusively from aliphatic carboxylic acids having 9-16 carbon atoms, preferably 10-12 carbon atoms in combination with a non-steroidal lipoid. The preparation may additionally contain a progestational steroid, an oestrogen or a precursor of an A-aromatic steroid.

Abstract: The invention relates to a new synthesis for the preparation of tetracyclic compounds of the general formula: ##STR1## as well as the pharmaceutically acceptable salts thereof, in which: n is the number 1 or 2,m is the number 1, if n=2 and the number 2, if n=1,R.sub.1 and R.sub.2 stand for hydrogen, hydroxy, halogen, lower alkyl (1-4 C), lower alkoxy (1-4 C) or trifluoromethyl andR.sub.3 represents hydrogen, alkyl (1-6 C), aralkyl (7-10 C) or an amino alkyl group (1-6 C), in which the nitrogen atom has been substituted by two alkyl groups (1-4 C), or the nitrogen atom forms part of a heterocyclic 5- or 6-membered ring,having valuable biological properties.

Abstract: An immunoassay based on the agglutination or the agglutination inhibition of a suspension of immunologically coated particles by the sample. Measurements are made with an apparatus having means for providing electromagnetic radiation at wavelengths equal to or less than the mean diameter of the particles and in a range of at least about 100 nm. The apparatus also includes means for measuring, at a predetermined angle, a portion of the radiation transmitted through a cuvette containing the reaction mixture.

Abstract: There are disclosed branched chain and cycloaliphatic esters of steroids having the formula: ##STR1## or the 5.alpha.H analog thereof, where R is H or CH.sub.3 ;R.sub.1 is H or CH.sub.3 ;R.sub.2 is H or CH.sub.3 ;R.sub.3 is H, OH, CH.sub.3 or Cl;R.sub.4 is H or C.sub.1 to C.sub.4 alkyl;R.sub.5 is H, C.sub.1 to C.sub.4 alkyl or CF.sub.3 ;R.sub.6 is H, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkoxy, halogen or .beta.-OH providing that when R.sub.6 is .beta.-OH, the steroid also contains 9.alpha.-F and further providing that R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 represent at least 4 and at most 5 hydrogen atoms, except in the case of a .DELTA..sup.1,4 -steroid, in which case R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are all hydrogen;R.sub.7 is H or CH.sub.3 ; ##STR2## providing the R.sub.8 is --OH or ##STR3## when the steroid has an aromatic ring A and the 3-position is substituted by ##STR4## R.sub.9 is ##STR5## where n is 0, 1 or 2;R.sub.10 is C.sub.1 to C.sub.10 alkyl;R.

Abstract: Novel peptides of the formula ##STR1## are disclosed (together with pharmaceutical compositions comprising a pharmaceutically effective amount of same) wherein X.sub.1 and X.sub.2 represent an hydroxy or amino group and B represents:(1) hydroxy or(2) an amino-acid residue selected from the group consisting of L-Asp-OH, L-Asn-OH, L-Glu-OH, L-Gln-OH, L-Ser-OH, or HN-A-COOH, wherein A is an alkylidene group from 1 to 6 carbon atoms;or a functional derivative thereof.These peptides have psychopharmacological properties; they are suitable for the treatment of certain mental disorders in which stimulation of brain function is desired, such as for the treatment of senility or amnesia.

Abstract: New and useful phenylalkylcarbohydroxamic acids are disclosed of the formula ##STR1## wherein: (a) R is selected from the group consisting of alkoxy of one to six carbon atoms, alkenyloxy of two to six carbon atoms, alkyl of one to six carbon atoms, and benzyloxy;(b) R.sub.1 and R.sub.2 are each selected from the group consisting of hydrogen, alkoxy of one to six carbon atoms, alkenyloxy of two to six carbon atoms, alkyl from one to six carbon atoms, and benzyloxy;(c) R.sub.3 and R.sub.4 are selected from the group consisting of hydrogen or alkyl of one to six carbon atoms;(d) R.sub.5 is hydrogen or R.sub.5 together with R.sub.3 or R.sub.4 represent methylene; and(e) n signifies the number 0 or 1,and non-toxic salts thereof, which novel compounds exert a pronounced inhibition of blood platelet aggregation and accelerate the disaggregation of platelet aggregates already formed.

Abstract: Novel cyclization substrates of the formula: ##STR1## wherein: (a) R.sub.1 is H or alkyl of one to four carbons;(b) R.sub.2 is H or alkyl of one to four carbons, with the proviso that R.sub.1 is H when R.sub.2 is alkyl; and with the proviso that P.sub.2 is H when R.sub.1 is alkyl;(c) R.sub.3 is a leaving group selected from the group consisting of OH, alkoxy of one to four carbons, alkoxyalkyoxy of from two to about four carbons, acyloxy of from about one to about seven carbons, and trialkylsilyloxy;(d) R.sub.4 is halogen, alkoxy of from one to four carbons, hydrocarbyl of from one to about four carbons, hydrocarbyl of from one to about four carbons substituted by one or more (1) halogens or (2) alkoxy moieties of from one to two carbons; and(e) R.sub.5 is H, alkyl of one to six carbons, hydroxy, or an esterified or estherified moiety of (1) less than eight carbons selected from the group consisting of alkoxy, trialkylsilyloxy, aralkyloxy, cyclo-alkoxy, and heterocyclo-oxy radicals; (2) .alpha.

Abstract: The invention relates to novel dibenzo[1,2;5,6]cyclohepta pyridine or -pyrrole derivatives, dibenzo[2,3;6,7]oxepino pyridine or pyrrole derivatives, dibenzo[2,3;6,7]thiepino pyridine or pyrrole derivatives and dibenzo[b,f]pyrido or pyrrolo azepine derivatives of general formula: ##STR1## as well as the pharmaceutically acceptable salts and nitrogen oxides thereof, whereinR.sub.1, R.sub.2, R.sub.3 and R.sub.4 each represent hydrogen, hydroxy, halogen, an alkyl (1-6 C) group, an alkoxy or alkylthio group in which the alkyl group contains 1-6 C-atoms, or a trifluoromethyl group,R.sub.5 represents hydrogen, an alkyl group with 1-6 carbon atoms or an aralkyl group with 7-10 carbon atoms,m is the number 1 or 2,X represents oxygen, sulphur, the group ##STR2## or the group --CH.sub.2 -- and R.sub.6 represents hydrogen or a lower alkyl group (1-4 C),having CNS-depressant activity and excellent antihistamine and antiserotonin activities.

Abstract: Novel cyclization substrates are disclosed of the formula ##STR1## wherein: (a) R.sub.1 is H or alkyl of one to four carbon atoms;(b) R.sub.2 is H or alkyl of one to four carbon atoms, with the proviso that R.sub.1 is H when R.sub.2 is alkyl, and with the proviso that R.sub.2 is H when R.sub.1 is alkyl;(c) R.sub.3 is a leaving group selected from the group consisting of hydroxy, alkoxy of one to four carbons, alkoxyalkoxy of two to four carbons, acyloxy of one to about seven carbons, and trialkylsilyloxy of less than fifteen carbons;(d) R.sub.4 is hydrocarbyl of one to four carbon atoms, a hydrocarbyl of one to two carbon atoms substituted by halogen or alkoxy of one to two carbons, or alkoxy of one to four carbon atoms; and(e) R.sub.5 and R.sub.5 ' each are H, OH, alkyl, trialkylsilyloxy, or an esterified or etherified hydroxy-group of about one to ten carbon atoms.

Abstract: New and useful phenylalkylcarbohydroxamic acids are disclosed of the formula ##STR1## wherein: (a) R is selected from the group consisting of alkoxy of one to six carbon atoms, alkenyloxy of two to six carbon atoms, alkyl of one to six carbon atoms, and benzyloxy;(b) R.sub.1 and R.sub.2 are each selected from the group consisting of hydrogen, alkoxy of one to six carbon atoms, alkenyloxy of two to six carbon atoms, alkyl from one to six carbon atoms, and benzyloxy;(c) R.sub.3 and R.sub.4 are selected from the group consisting of hydrogen or alkyl of one to six carbon atoms;(d) R.sub.5 is hydrogen or R.sub.5 together with R.sub.3 or R.sub.4 represent methylene; and(e) n signifies the number 0 to 1,and non-toxic salts thereof, which novel compounds exert a pronounced inhibition of blood platelet aggregation and accelerate the disaggregation of platelet aggregates already formed.

Abstract: New and useful stable peroxidase compositions are disclosed which are particularly useful as reagents in enzyme immunoassay (EIA) tests. The novel peroxidase compositions contain polyvalent ions of groups 3 and 4 of the Periodic Table. These novel compositions are stable even in low concentrations, and are relatively invulnerable to freeze-drying. Preferably, the polyvalent ions selected are those of Al, Zn, Mg, Fe, and Cu.